GLOW Peptide

GHK-Cu, BPC-157 & TB-500 Research Combination

Dragon Pharma GLOW Blend is a three-peptide lyophilized research combination delivering GHK-Cu, BPC-157, and TB-500 in a single 70 mg vial. Each component is independently studied across distinct but overlapping lines of regenerative biology research — copper-mediated matrix remodeling, cytoprotective and angiogenic signaling, and actin-dependent cytoskeletal dynamics — and Dragon Pharma GLOW Blend allows laboratories to investigate how these three mechanisms interact simultaneously under controlled in vitro conditions.

The blend is formulated at a deliberately asymmetric ratio: 50 mg GHK-Cu as the dominant matrix-remodeling component, with 10 mg BPC-157 and 10 mg TB-500 providing complementary angiogenic and cytoskeletal research axes. This composition reflects the distinct research roles of each compound — GHK-Cu's activity is concentration-dependent from the picomolar to nanomolar range in published collagen synthesis assays, while BPC-157 and TB-500 are studied in the nanomolar to low-micromolar range for signaling and motility endpoints. Dragon Pharma GLOW Blend ships as a single lyophilized powder without fillers, allowing reconstitution to any working concentration appropriate to the experimental design.

Every Dragon Pharma GLOW Blend vial is manufactured to research-grade specifications with each component verified at ≥99% HPLC purity. For research use only.

Compound Specifications

What Research Shows About Dragon Pharma GLOW Blend Components

Laboratory studies of the three Dragon Pharma GLOW Blend components describe distinct but overlapping mechanisms across vascular, tissue-repair, and matrix models. Each component contributes a separate and non-redundant research axis to the blend.

GHK-Cu — Copper-Mediated Matrix Remodeling

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is the dominant component in Dragon Pharma GLOW Blend at 50 mg per vial. The Gly-His-Lys tripeptide forms a stable complex with divalent copper ions (Cu²⁺), and this copper coordination is integral to its characterized biological activity in matrix biology research models.

Maquart, Pickart, Laurent, Gillery, Monboisse, and Borel (1988, FEBS Letters) demonstrated stimulation of collagen synthesis in fibroblast cultures by the GHK-Cu complex at picomolar to nanomolar concentrations — establishing the concentration-dependent activity window relevant for experimental design with the Dragon Pharma GLOW Blend GHK-Cu component. The copper complex directly influenced type I and type III procollagen production in cultured dermal fibroblasts, providing an extracellular matrix synthesis model well-characterized for in vitro replication.

Pickart and Margolina (2018, International Journal of Molecular Sciences) published gene-profiling analysis linking GHK-Cu to modulation of over 4,000 human genes associated with tissue-repair, antioxidant pathway regulation, anti-inflammatory signaling, and collagen turnover. The breadth of this gene regulatory profile positions GHK-Cu as a research tool relevant across matrix biology, wound healing pathway investigation, and oxidative stress response models simultaneously.

BPC-157 — Angiogenic Signaling and Cytoprotective Research

BPC-157 (Body Protection Compound 157) is a synthetic 15-residue pentadecapeptide studied primarily in angiogenesis and cell-survival research models. In Dragon Pharma GLOW Blend it contributes the vascular biology research axis alongside GHK-Cu's matrix-remodeling activity.

Hsieh, Liu, Wang, Huang, Lin, Ko, Wang, Chang, and Pang (2016, Journal of Molecular Medicine) documented that BPC-157 in vascular endothelial cell cultures was associated with increased expression and internalization of VEGFR2 (vascular endothelial growth factor receptor 2) and with activation of the VEGFR2-Akt-eNOS signaling pathway in tube-formation assays. This pro-angiogenic activity through a VEGFR2-dependent mechanism provides a well-characterized endpoint for studying the BPC-157 component within Dragon Pharma GLOW Blend's multi-mechanism research context.

Chang, Tsai, Lin, Hsu, and Pang (2011, Journal of Applied Physiology) demonstrated BPC-157's effects in tendon explant and fibroblast cultures — including greater fibroblast outgrowth, cell survival under oxidative stress conditions, and cell migration through FAK-paxillin pathway activation. The overlap between BPC-157's cytoprotective fibroblast activity and GHK-Cu's collagen synthesis stimulation makes these two Dragon Pharma GLOW Blend components particularly relevant for combined extracellular matrix research models.

TB-500 — Actin Dynamics and Cytoskeletal Research

TB-500 corresponds to the actin-binding region of thymosin beta-4 (Ac-Ser-Asp-Lys-Pro sequence and the 43-residue fragment), contributing the cytoskeletal dynamics research axis to Dragon Pharma GLOW Blend.

Xue, Leyrat, Grimes, and Robinson (2014, PNAS) established the structural basis of thymosin-β4's interaction with profilin and G-actin, confirming that the TB-500 sequence sequesters monomeric G-actin and regulates filament assembly through competitive exchange with profilin. This mechanistic characterization provides the structural foundation for interpreting cytoskeletal dynamics data generated with the TB-500 component of Dragon Pharma GLOW Blend.

Malinda, Sidhu, Mani, Banaudha, Maheshwari, Goldstein, and Kleinman (1999, Journal of Investigative Dermatology) documented thymosin beta-4 association with increased reepithelialization and keratinocyte migration in a full-thickness wound model, providing an in vivo-adjacent endpoint for contextualization of TB-500 cell migration data generated in vitro. In the Dragon Pharma GLOW Blend context, TB-500's actin-dependent keratinocyte motility activity creates a complementary layer to BPC-157's FAK-paxillin-mediated fibroblast migration — two distinct migration pathways studied simultaneously in the same experimental system.

Dragon Pharma GLOW Blend — Research Applications

Why Dragon Pharma GLOW Blend: The Research Rationale

Each component in Dragon Pharma GLOW Blend targets a distinct biological layer of tissue repair and matrix biology:

• GHK-Cu operates at the extracellular matrix level — directly stimulating collagen synthesis, modulating lysyl oxidase cross-linking activity, and regulating a broad gene network associated with antioxidant and tissue-repair pathways
• BPC-157 operates at the vascular and cytoprotective signaling level — activating VEGFR2-mediated angiogenic pathways and supporting cell survival and migration through FAK-paxillin signaling
• TB-500 operates at the cytoskeletal dynamics level — sequestering G-actin to regulate filament assembly and enabling the actin-dependent cell motility required for tissue repair processes

These three research axes are mechanistically non-redundant — GHK-Cu's copper coordination chemistry, BPC-157's receptor-mediated signaling, and TB-500's direct actin-binding activity represent three entirely different molecular engagement modes. Combining them in Dragon Pharma GLOW Blend allows researchers to study how these mechanisms interact, whether their effects are additive or synergistic in shared cell models, and which pathways dominate under specific experimental conditions — research questions that require all three compounds to be present simultaneously in the same experimental system.

Key Features of Dragon Pharma GLOW Blend

• ✔ Three mechanistically non-redundant research axes in one vial — copper-mediated matrix remodeling (GHK-Cu), VEGFR2 angiogenic and cytoprotective signaling (BPC-157), and G-actin-dependent cytoskeletal dynamics (TB-500)
• ✔ 70 mg total vial content at research-optimized composition — 50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500; ratios reflect the distinct concentration ranges at which each component's published activity has been characterized
• ✔ ≥99% HPLC purity for each individual component — Dragon Pharma quality standard applied per compound before blending
• ✔ Six peer-reviewed publications across five research domains — each GLOW component is supported by published data in FEBS Letters, IJMS, Journal of Molecular Medicine, Journal of Applied Physiology, PNAS, and Journal of Investigative Dermatology
• ✔ No fillers or excipients — lyophilized blend without additives that could confound downstream assay results
• ✔ Water-soluble across all three components — no organic co-solvents required for standard laboratory working concentrations
• ✔ Dragon Pharma pharmaceutical-grade manufacturing — consistent production standards applied across Dragon Pharma's full research peptide catalog
• ✔ Independent COA per Dragon Pharma batch — lot-traceable quality documentation available per production run

Product Summary

Dragon Pharma GLOW Blend is a 70 mg lyophilized three-peptide research combination containing GHK-Cu (50 mg, CAS 89030-95-5), BPC-157 (10 mg, CAS 137525-51-0), and TB-500 (10 mg, CAS 77591-33-4). Each component is verified at ≥99% HPLC purity. The blend allows simultaneous laboratory investigation of copper-mediated matrix remodeling, VEGFR2-mediated angiogenic and cytoprotective signaling, and actin-dependent cytoskeletal dynamics — three mechanistically non-redundant research axes in a single Dragon Pharma vial. Research applications include endothelial tube-formation assays, collagen synthesis and matrix-remodeling models, fibroblast outgrowth and migration studies, G-actin sequestration and filament-assembly characterization, and multi-mechanism tissue repair pathway research. For research use only.

Research domains: Angiogenesis • Extracellular matrix biology • Tissue repair signaling • Cytoskeletal dynamics • Cell migration • Multi-mechanism regenerative research